Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This will be a single arm, open label pilot to test the combination of dapagliflozin, a
commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in
patients with HR+/HER2- mBC. The objective of this study is to determine if the addition of
dapagliflozin to the combination of alpelisib and fulvestrant leads to significant reduction
in all-grade hyperglycemia.